pembrolizumab and lenvatinib

DRUG4 trials

Sponsors

National University Hospital, Singapore, University College, London, Peking Union Medical College Hospital, Prof. Dr. Remi A. Nout

Conditions

Adenocarcinoma or Adeno-squamous Carcinoma Stage IB3-IIIC2AdenocarcinomasBiliary Tract Neoplasms ImmunotherapyCervical Cancer by FIGO Stage 2018Hepatocellular CarcinomaRecurrent GynecologicalSquamous Cell Carcinoma FIGO 2018 Stage IIIA, IIIB, IIIC1-IIIC2

Phase 2

Trial of Lenvatinib Plus PembrolizumAb in Recurrent Gynecological Clear Cell Adenocarcinomas (LARA)

National University Hospital, SingaporeAdenocarcinomas, Recurrent Gynecological

Start: 2021-02-18End: 2025-01-31Target: 10Updated: 2021-10-21

Perioperative Pembrolizumab and Lenvatinib in Resectable Hepatocellular Carcinoma (HCC)

RecruitingNCT05185739

University College, LondonHepatocellular Carcinoma

Start: 2022-08-25End: 2030-07-31Target: 60Updated: 2024-12-06

Pembrolizumab With or Without Lenvatinib or Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer

RecruitingNCT06230471

Peking Union Medical College HospitalBiliary Tract Neoplasms Immunotherapy

Start: 2023-01-09End: 2026-04-30Target: 60Updated: 2025-12-09

Pembrolizumab and Lenvatinib in Patients With High Risk Locally Advanced Cervix Cancer

Not yet recruitingNCT07368985

Prof. Dr. Remi A. NoutAdenocarcinoma or Adeno-squamous Carcinoma Stage IB3-IIIC2, Cervical Cancer by FIGO Stage 2018, Squamous Cell Carcinoma FIGO 2018 Stage IIIA, IIIB, IIIC1-IIIC2

Start: 2026-03-01End: 2029-10-01Target: 87Updated: 2026-01-27

Related Papers

Pembrolizumab plus lenvatinib in recurrent gynaecological clear cell carcinoma (LARA): a multicentre, single-arm, phase 2 trial.

2026-01-15